Additional Ring Containing Patents (Class 546/342)
-
Publication number: 20120071661Abstract: A chiral ionic compound comprising an alkyl substituted imidazolium or pyridinium cationic core having an alkyl ester side chain (-alkyl-C(O)O—) directly linked to the core and an associated counter anion, characterized in that the —O— atom of the ester side chain is linked to an alpha, a beta or a gamma hydroxycarboxylic acid functionality via the alpha, beta or gamma hydroxy of the acid functionality and the hydroxycarboxylic acid functionality has at least one asymmetric carbon, or characterized in that an —N? atom of the alkyl substituted imidazolium or pyridinium cationic core is substituted with an alpha, a beta or a gamma hydroxy group of a alpha, a beta or a gamma hydroxycarboxylic acid functionality and the hydroxycarboxylic acid functionality has at least one asymmetric carbon. The chiral ionic liquids (CILs) may be used as novel solvents, in particular for organic synthesis. The CILs have the potential to induce asymmetry into substrates or catalysts in a variety of organic transformations.Type: ApplicationFiled: February 24, 2010Publication date: March 22, 2012Inventors: Nicholas Gathergood, Bruce Pegot, Ian Beadham, Monika Gurbisz, Mukund D. Ghavre, Saibh Morrissey
-
Patent number: 8124783Abstract: Disclosed herein the process for producing 1-benzyl-4-[(5,6-dimethoxy-1-indanon-2yl)methyl]piperidine or its salt thereof employing novel intermediates.Type: GrantFiled: December 30, 2004Date of Patent: February 28, 2012Assignee: Jubilant Organosys LimitedInventors: Shailendra Kumar Dubey, Amit Kumar Sharma, Beena S. Rani, Soumendu Paul, Rajesh Kumar Thaper, Dubey Sushil Kumar, Jag Mohan Khanna
-
Patent number: 8076324Abstract: The present invention relates to di(hetero)arylcyclohexane derivatives of the formula I, in which Ar1, Ar2, R1 and R2 have the meanings indicated in the claims. The compounds of the formula I are valuable pharmaceutical active compounds which inhibit ATP-sensitive potassium channels in the heart muscle and are suitable, for example, for the treatment of disorders of the cardiovascular system such as arrhythmias or a decreased contractility of the heart, such as can occur, for example, in coronary heart disease, cardiac insufficiency or cardiomyopathies. In particular, they are suitable for the prevention of sudden cardiac death. The invention furthermore relates to processes and intermediates for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them.Type: GrantFiled: December 3, 2009Date of Patent: December 13, 2011Assignee: Sanofi-AventisInventors: Thomas Bohme, Uwe Gerlach, Dirk Gretzke, Heinz-Werner Kleemann, Stefania Pfeiffer-Marek, Henning Vollert, Jean-Michel Altenburger, Sergio Mallart
-
Publication number: 20110245244Abstract: Novel compounds of the general formula (I), the use of these compounds as pharmaceutical compositions, pharmaceutical compositions comprising the compounds and methods of treatment employing these compounds and compositions. The present compounds are activators of PPAR? and should be useful for treating conditions mediated by the same.Type: ApplicationFiled: April 4, 2011Publication date: October 6, 2011Applicant: HIGH POINT PHARMACEUTICALS, LLCInventors: Per Sauerberg, Pavel Pihera, Zdenek Polivka, Miroslav Havranek, Ingrid Pettersson, John Patrick Mogensen
-
Patent number: 8030354Abstract: The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula I: where the definitions of the variables are provided herein. The present invention also provides compositions that include, and methods for using, the compounds in preparing medicaments and for treating metabolic disorders such as, for example, type II diabetes.Type: GrantFiled: October 3, 2008Date of Patent: October 4, 2011Assignee: Amgen Inc.Inventors: Sean P. Brown, Qiong Cao, Paul John Dransfield, Xiaohui Du, Zice Fu, Jonathan Houze, Xian Yun Jiao, Yong-Jae Kim, Todd J. Kohn, SuJen Lai, An-Rong Li, Daniel Lin, Jiwen Liu, Jian Luo, Julio C. Medina, Jeffrey D. Reagan, Vatee Pattaropong, Margrit Schwarz, Wang Shen, Yongli Su, Gayathri Swaminath, Marc Vimolratana, Yingcai Wang, Yumei Xiong, Li Yang, Ming Yu, Jie Zhang, Liusheng Zhu
-
Patent number: 8026239Abstract: A method of treating a malignant tumor selected from the group consisting of leukemia, colorectal cancer, ovarian cancer, oral cancer, lung carcinoma, breast carcinoma, prostate carcinoma, and melanoma by administering to a patient in need thereof an effective amount of at least one compound represented by formula (1) wherein A, X, Q, R1-3, and n are defined herein.Type: GrantFiled: March 11, 2010Date of Patent: September 27, 2011Assignee: Bayer Schering Pharma AktiengesellschaftInventors: Tsuneji Suzuki, Tomoyuki Ando, Katsutoshi Tsuchiya, Osamu Nakanishi, Akiko Saito, Takashi Yamashita, Yoshinori Shiraishi, Eishi Tanaka
-
Patent number: 7968725Abstract: The present invention relates to compounds of Formula I as shown below, wherein the definitions of A, X, R1 R2, R3, R4, R5, R6, R7, R8, and R9 are provided in the specification. Compounds of Formula I are useful for the treatment of diseases associated with ?-secretase activity, including Alzheimer's disease.Type: GrantFiled: June 5, 2009Date of Patent: June 28, 2011Assignee: Janssen Pharmaceutica N.V.Inventor: Tianbao Lu
-
Publication number: 20110152315Abstract: There is provided novel compounds capable of modulating the G-protein-coupled receptor GPR40, compositions comprising the compounds, and methods for their use for controlling insulin levels in vivo and for the treatment of conditions such as type I1 diabetes, hypertension, ketoacidosis, obesity, glucose intolerance, and hypercholesterolemia and related disorders associated with abnormally high or low plasma lipoprotein, triglyceride or glucose levels.Type: ApplicationFiled: July 23, 2009Publication date: June 23, 2011Inventors: Trond Ulven, Elisabeth Christiansen
-
Publication number: 20110144075Abstract: Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols are useful as inhibitors of the phosphodiesterase 4 (PDE4) enzyme.Type: ApplicationFiled: February 22, 2011Publication date: June 16, 2011Applicant: Chiesi Farmaceutici S.p.A.Inventors: Maurizio Delcanale, Elisabetta Armani, Gabriele Amari
-
Publication number: 20110144070Abstract: Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols are useful as inhibitors of the phosphodiesterase 4 (PDE4) enzyme.Type: ApplicationFiled: February 22, 2011Publication date: June 16, 2011Applicant: Chiesi Farmaceutici S.p.A.Inventors: Maurizio Delcanale, Elisabetta Armani, Gabriele Amari
-
Publication number: 20110105545Abstract: Disclosed are compounds of formula: that inhibiting GPBP activity, making them useful as therapeutics in antibody-mediated disorders, drug-resistant cancer, inflammation, protein misfolding and ER stress-mediated disorders, and aberrant apoptosis.Type: ApplicationFiled: November 5, 2010Publication date: May 5, 2011Applicant: FIBROSTATIN, S.L.Inventors: JUAN SAUS, SANTOS FUSTERO, JUAN F. SANZ-CERVERA, ENRIQUE PEREZ-PAYA, RAUL BLASCO, FRANCISCO REVERT-ROS, FERNANDO REVERT
-
Publication number: 20110105432Abstract: The present invention relates to a compound represented by the formula (I), a salt thereof, an N-oxide form thereof, a solvate thereof, or a prodrug thereof, and a medicament containing the same. The compound represented by the formula (I) has an ability to bind to an S1P receptor (particularly, EDG-1, EDG-6, and/or EDG-8) and is useful for preventing and/or treating for rejection to transplantation, graft-versus-host disease, autoimmune diseases, allergic diseases, neurodegenerating diseases, and the like. wherein all symbols are described in the specification.Type: ApplicationFiled: January 7, 2011Publication date: May 5, 2011Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Hiromu HABASHITA, Haruto Kurata, Shinji Nakade
-
Publication number: 20110105544Abstract: The invention provides novel compounds of formula (I), wherein: R1 is a radical derived from one of the known ring systems; R2 is a phenyl radical optionally substituted; Xn represents a birradical selected from the group consisting of: —(CH2)1-4—, (C2-C4)-alkenyl, (C2-C4)alkynyl, —S—(CH2)1-3—#, and —(CH2)1-3—O—#; wherein the symbol # indicates the position at which Xn is attached to R1; Yn is a birradical selected from the group consisting of: —(CH2)2-4—, —S—(CH2)1-3#, and —O—(CH2)1-3—#; wherein the symbol # indicates the position at which Yn is attached to R2; and R3 is a radical selected from the group consisting of: —OR4. The compounds of formula (I) are useful in the treatment of cancer.Type: ApplicationFiled: December 18, 2008Publication date: May 5, 2011Inventors: Juan Aymami Bofarull, Franck Camille Nicolas Chevalier, Montserrat Soler Lopez, Maria Teresa Luque Garrofe, Marc Martinell Pedemonte
-
Publication number: 20110059939Abstract: Compounds comprising formula (I) or a pharmaceutically acceptable salt thereof, a dashed line represent the presence or absence of a double bond, are disclosed, wherein J1, J2, U1, B, Y, and A are as described in claims 1-12. Methods, compositions, and medicaments related thereto are also disclosed, for treating glaucoma, inflammatory bowel disease and baldness.Type: ApplicationFiled: May 4, 2009Publication date: March 10, 2011Applicant: ALLERGAN ,INCInventors: David W. Old, Vinh X. Ngo
-
Patent number: 7893094Abstract: The present invention is directed to the amphiphilic pyridinium compounds, such as for suppressing IL-8 secretion and production. The present invention further provides methods of making and using such compounds for the treatment of the IL-8 related diseases, such as cystic fibrosis.Type: GrantFiled: June 28, 2004Date of Patent: February 22, 2011Assignees: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., National Institutes of Health (NIH)Inventors: Harvey B. Pollard, Kenneth Jacobson
-
Patent number: 7893268Abstract: Epothilone analogues include a molecular scaffold which holds at least one segment of epothilone in a predetermined orientation and which rigidities a region between the macrolactone ring and the aromatic side-chain.Type: GrantFiled: July 20, 2006Date of Patent: February 22, 2011Assignee: University of ToledoInventors: Viranga Tillekeratne, Richard D. Hudson, Mamoun Alhamadsheh
-
Publication number: 20110040094Abstract: Compounds that are 1,3,4-trisubstituted benzenes which modulate (e.g., inhibit) the activity of ?-secretase. The compounds are expected to reduce the level of A?42 in patients and be useful in the treatment of diseases (e.g., Alzheimer's disease) characterized by elevated levels of A?42 and/or the formation of A? plaques.Type: ApplicationFiled: September 15, 2008Publication date: February 17, 2011Applicant: ENVIVO PHARMACEUTICALS, INC.Inventors: Gideon Shapiro, Richard Chesworth
-
Publication number: 20110021534Abstract: The present invention relates to 2-(substituted sulphur, sulphone or sulphoxide)-3-(substituted phenyl) propionic acid derivatives, 2-(substituted oxygen)-3-(substituted phenyl) propionic acid derivatives, benzoic acid derivatives, and derivatives of 2-methyl-2-(phenoxy or phenylthio)propanoic acid and 2-(methylor ethyl)-2-(phenoxy or phenylthio)butanoic acid, to processes for preparing such compounds, to their use in the treatment of inflammatory conditions, and to pharmaceutical compositions containing them.Type: ApplicationFiled: March 7, 2008Publication date: January 27, 2011Applicant: ALBIREO ABInventors: Anders Broo, Johan Gottfries, Michael Kossenjans, Li Lanna, Eva-Lotte Lindstedt-Alstermark, Kristina A. Nilsson, Bengt Ohlsson, Maria Thorstensson, Maria Boije, Olof Sjogren
-
Publication number: 20100331370Abstract: Isobenzofuran analogs of sclerophytin A are prepared in a highly concise fashion via an aldol-cycloaldol sequence. The analogs exhibit IC50's as low as 1 ?M in growth inhibitory studies against KB3 cells using an MTT assay. Preferred analogs have one of the following structural formulas, where R is hydrogen or a substituted or unsubstituted lower alkyl group and Ar is a substituted or unsubstituted aryl group.Type: ApplicationFiled: June 30, 2010Publication date: December 30, 2010Inventor: Matthias C. McIntosh
-
Publication number: 20100298367Abstract: The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula I or the general formula III: where the definitions of the variables are provided herein. The present invention also provides compositions that include, and methods for using, the compounds in preparing medicaments and for treating metabolic disorders such as, for example, type II diabetes.Type: ApplicationFiled: March 4, 2009Publication date: November 25, 2010Inventors: Sean P. Brown, Paul J. Dransfield, Jonathan Houze, Todd J. Kohn, Jiwen Liu, Julio Medina, Vatee Pattaropong, Wang Shen, Marc Vimolratana, Yingcai Wang, Ming Yu, Liusheng Zhu
-
Patent number: 7829613Abstract: The present invention relates to a splayant, that is, an intercalant/exfoliant, comprising an azinium compound capable of splaying a layered material.Type: GrantFiled: March 11, 2009Date of Patent: November 9, 2010Assignee: Eastman Kodak CompanyInventors: Debasis Majumdar, Deepak Shukla
-
Patent number: 7829721Abstract: The invention relates to compounds of the general formula (I), and to their use as caspase-10 inhibitors, especially for the treatment of diabetic retinopathy.Type: GrantFiled: November 2, 2005Date of Patent: November 9, 2010Assignee: Merck Patent GmbHInventors: Claude Lardy, Marc Lecomte, Catherine Vidal, Thierry Convard, Stéphane Yvon, Marie Noelle Denuault, Denis Descours
-
Publication number: 20100267778Abstract: The present invention relates to a compound represented by formula (I): wherein ring A, ring B and ring D each independently represents a cyclic group which may have a substituent(s); W is a spacer having 1 to 8 atom(s) in its main chain; X is a spacer having 1 to 2 atom(s) in its main chain; Y is a binding bond or a spacer having 1 to 8 atom(s) in its main chain; and Z is an acidic group, or a salt thereof, a solvate thereof or a prodrug thereof. The compound represented by formula (I) has a PPAR ? agonistic action and is useful as a preventive and/or treating agent for diseases where sugar and lipid metabolisms are abnormal (diabetes, hyperlipemia, arteriosclerosis, cardiovascular diseases, obesity and metabolic syndrome or the like), hypertension, circulatory diseases and skin inflammation diseases.Type: ApplicationFiled: August 3, 2004Publication date: October 21, 2010Inventors: Shinya Kusuda, Yoshisuke Nakayama, Masaki Ima, Hisao Tajima, Sachiko Kato
-
Patent number: 7816523Abstract: This application relates to a substituted hydroxyphenyl ketone compound of formula I, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition thereof and its use in treating migraine. This application also relates to processes for preparing a compound of formula I, and intermediate compounds useful therein.Type: GrantFiled: August 28, 2009Date of Patent: October 19, 2010Assignee: Eli Lilly and CompanyInventors: Thomas Daniel Aicher, Guillermo S. Cortez, Todd Michael Groendyke, Albert Khilevich, James Allen Knobelsdorf, Fredrik Pehr Marmsater, Jeffrey Michael Schkeryantz, Tony Pisal Tang
-
Patent number: 7807838Abstract: The present invention relates to methods and compounds useful in the preparation of compounds of the formula (I).Type: GrantFiled: August 16, 2006Date of Patent: October 5, 2010Assignee: Pfizer Inc.Inventors: Christopher Frederick Matthews, Robert William Scott, John Lloyd Tucker
-
Publication number: 20100249139Abstract: The present invention relates to compounds of formula I wherein R1a to R1e and R2 to R5 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are glucocorticoid receptor antagonists useful for the treatment and/or prevention of diseases such as diabetes, dyslipidemia, obesity, hypertension, cardiovascular diseases, adrenal imbalance or depression.Type: ApplicationFiled: March 19, 2010Publication date: September 30, 2010Inventors: Daniel Hunziker, Christian Lerner, Werner Mueller, Ulrike Obst Sander, Philippe Pflieger, Pius Waldmeier
-
Publication number: 20100234432Abstract: The present application relates to novel substituted 6-phenylnicotinic acid derivatives, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, preferably for the treatment and/or prophylaxis of cardiovascular disorders, in particular dyslipidaemias, arteriosclerosis and heart failure.Type: ApplicationFiled: August 26, 2008Publication date: September 16, 2010Applicant: BAYER ANIMAL HEALTH GMBHInventors: Lars Baerfacker, Barbara Albrecht-Kuepper, Peter Kolkhof, Yolanda Cancho Grande, Adam Nitsche, Heinrich Meier, Carsten Schmeck, Jens Schamberger, Klemens Lustig
-
Publication number: 20100222380Abstract: Antimitotic agents comprising a modified chalcone or modified chalcone derivative are disclosed. The modified chalcone or modified chalcone derivative compounds are of the general formula CHAL-LIN-COV, wherein CHAL is a chalcone or chalcone derivative portion, LIN is an optional linker portion, and COV is a covalent bonding portion (e.g., an ?,?-unsaturated thiol ester group). The modified chalcone or modified chalcone derivative compounds provide an improved method of interference with tubulin polymerization, for example by covalent (and essentially irreversible) bonding between tubulin and the covalent bonding portion, potentially resulting in a decrease in tumor size and/or disappearance of the cancer, to the benefit of cancer patients.Type: ApplicationFiled: May 10, 2010Publication date: September 2, 2010Applicant: ARIZONA BIOMEDICAL RESEARCH COMMISSIONInventors: Seth D. Rose, Rosemarie F. Hartman
-
Publication number: 20100204256Abstract: 1-Phenyl-2-pyridinyl alkyl alcohol compounds are effective as inhibitors of the phosphodiesterase 4 (PDE4) enzyme and may be used to prevent and/or treat certain diseases or conditions.Type: ApplicationFiled: February 5, 2010Publication date: August 12, 2010Applicant: Chiesi Farmaceutici S.p.A.Inventors: Gabriele Amari, Elisabetta Armani, Maurizio Delcanale
-
Publication number: 20100204472Abstract: This invention relates to novel indane acetic acid derivatives which are useful in the treatment of diseases such as diabetes, obesity, hyperlipidemia, and atherosclerotic diseases. The invention also relates to intermediates useful in preparation of indane acetic derivatives and to methods of preparation.Type: ApplicationFiled: April 13, 2010Publication date: August 12, 2010Inventors: Louis-David Cantin, Soongyu Choi, Roger B. Clark, Martin F. Hentemann, Xin Ma, Joachim Rudolph, Sidney X. Liang, Christiana Akuche, Rico C. Lavoie, Libing Chen, Dyuti Majumdar, Philip L. Wickens
-
Publication number: 20100204206Abstract: Di(hetero)arylcyclohexane derivatives, their preparation, their use and pharmaceutical compositions comprising them The present invention relates to di(hetero)arylcyclohexane derivatives of the formula I, in which Ar1, Ar2, R1 and R2 have the meanings indicated in the claims. The compounds of the formula I are valuable pharmaceutical active compounds which inhibit ATP-sensitive potassium channels in the heart muscle and are suitable, for example, for the treatment of disorders of the cardiovascular system such as arrhythmias or a decreased contractility of the heart, such as can occur, for example, in coronary heart disease, cardiac insufficiency or cardiomyopathies. In particular, they are suitable for the prevention of sudden cardiac death. The invention furthermore relates to processes and intermediates for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them.Type: ApplicationFiled: December 3, 2009Publication date: August 12, 2010Applicant: SANOFI-AVENTISInventors: Thomas BOHME, Uwe GERLACH, Dirk GRETZKE, Heinz-Werner KLEEMANN, Stefania PFEIFFER-MAREK, Henning VOLLERT, Jean-Michel ALTENBURGER, Sergio MALLART
-
Publication number: 20100190693Abstract: In accordance with the present invention, it has been discovered that glucose and incretin hormones promote pancreatic islet cell survival via the calcium and cAMP dependent induction, respectively, of the transcription factor CREB. Specifically, a signaling module has been identified which mediates cooperative effects of calcium and cAMP on islet cell gene expression by stimulating the dephosphorylation and nuclear entry of TORC2, a cytoplasmic CREB coactivator. The module comprises a cAMP regulated snfl-like kinase called SIK2 and the calcium regulated phosphatase calcineurin, both of which associate with TORC2 in the cytoplasm. TORC2 is repressed under basal conditions through a phosphorylation dependent interaction with 14-3-3 proteins. cAMP and calcium signals stimulate CREB target gene expression via complementary effects on TORC2 dephosphorylation; cAMP disrupts TORC2-associated activity of SIK2 or related family members, whereas calcium induces TORC2 dephosphorylation via calcineurin.Type: ApplicationFiled: December 19, 2008Publication date: July 29, 2010Inventor: Marc R. Montminy
-
Patent number: 7745445Abstract: The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of the Peroxisome Proliferator-Activated Receptor (PPAR) families, particularly the activity of PPAR?.Type: GrantFiled: May 13, 2005Date of Patent: June 29, 2010Assignee: IRM LLCInventors: Robert Epple, Mihai Azimioara
-
Publication number: 20100137323Abstract: The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula I: where the definitions of the variables Q, L1, , L2,M, X, L3, and A are provided herein. The present invention also provides compositions that include, and methods for using, the compounds in preparing medicaments and for treating metabolic disorders such as, for example, type II diabetes.Type: ApplicationFiled: January 29, 2010Publication date: June 3, 2010Applicant: Amgen Inc.Inventors: Sean P. Brown, Paul Dransfield, Jonathan B. Houze, Jinqian Liu, Jiwen Liu, Zhihua Ma, Julio C. Medina, Vatee Pattaropong, Michael J. Schmitt, Rajiv Sharma, Yingcai Wang
-
Publication number: 20100137347Abstract: Disclosed herein is a compound of the formula (I). Therapeutic methods, compositions, and medicaments, related thereto are also disclosed.Type: ApplicationFiled: January 21, 2008Publication date: June 3, 2010Applicant: ALLERGAN, INC.Inventors: Yariv Donde, Jeremiah H. Nguyen
-
Patent number: 7671066Abstract: The invention relates to inhibitors of the phosphodiesterase 4 (PDE4) enzyme. More particularly, the invention relates to compounds that are derivatives of 1-phenyl-2-pyridynyl alkylene alcohols, methods of preparing such compounds, compositions containing them and therapeutic use thereof.Type: GrantFiled: July 12, 2007Date of Patent: March 2, 2010Assignee: Chiesi Farmaceutici S.p.A.Inventors: Gabriele Amari, Elisabetta Armani, Eleonora Ghidini
-
Publication number: 20100022583Abstract: The present invention relates to compounds of Formula I as shown below, wherein the definitions of A, X, R1 R2, R3, R4, R5, R6, R7, R8, and R9 are provided in the specification. Compounds of Formula I are useful for the treatment of diseases associated with ?-secretase activity, including Alzheimer's disease.Type: ApplicationFiled: June 5, 2009Publication date: January 28, 2010Inventor: Tianbao Lu
-
Publication number: 20090299065Abstract: A method for preparing an alkali metal salt comprising: (a) condensing a disilyloxydiene with an aldehyde in the presence of a titanium (IV) catalyst in an inert solvent to form a 5(S)-hydroxy-3-ketoester; (b) reducing the 5(S)-hydroxy-3-ketoester to a 3(R),5(S)-dihydroxyester in the presence of a di(lower alkyl)methoxyborane; and (c) hydrolyzing the 3(R),5(S)-dihydroxyester in the presence of an aqueous base to form an alkali metal salt.Type: ApplicationFiled: July 2, 2009Publication date: December 3, 2009Inventors: Guang-Pei Chen, Prasad Koteswara Kapa, Eric M. Loeser, Ulrich Beutler, Werner Zaugg, Michael John Girgis
-
Publication number: 20090275554Abstract: The present invention relates to a compound represented by the formula (I), a salt thereof, an N-oxide form thereof, a solvate thereof, or a prodrug thereof, and a medicament containing the same. The compound represented by the formula (I) has an ability to bind to an S1P receptor (particularly, EDG-1, EDG-6, and/or EDG-8) and is useful for preventing and/or treating for rejection to transplantation, graft-versus-host disease, autoimmune diseases, allergic diseases, neurodegenerating diseases, and the like. wherein all symbols are described in the specification.Type: ApplicationFiled: December 12, 2005Publication date: November 5, 2009Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Hiromu Habashita, Haruto Kurata, Shinji Nakade
-
Publication number: 20090270499Abstract: This invention relates to a process for synthesizing Atazanvir, including novel intermediates and novel steps to various intermediates along the synthetic pathway.Type: ApplicationFiled: April 24, 2008Publication date: October 29, 2009Applicant: OXYRANE (UK) LIMITEDInventor: Weiping Chen
-
Publication number: 20090258904Abstract: Epothilone analogues include a molecular scaffold which holds at least one segment of epothilone in a predetermined orientation and which rigidities a region between the macrolactone ring and the aromatic side-chain.Type: ApplicationFiled: July 20, 2006Publication date: October 15, 2009Inventors: Viranga Tillekeratne, Richard D. Hudson, Mamoun Alhamadsheh
-
Publication number: 20090221547Abstract: The present invention relates to immunosuppressants, processes for their production, their uses and pharmaceutical compositions containing them. The invention provides a novel class of compounds useful in the treatment or prevention of diseases or disorders mediated by lymphocyte interactions, particularly diseases associated with EDG receptor mediated signal transduction. This application relates to compounds selected from Formula (Ia), (Ib), (Ic) and (Id).Type: ApplicationFiled: August 22, 2006Publication date: September 3, 2009Applicant: IRM LLCInventors: Wenqi Gao, Yongqin Wan, Jiqing Jiang, Yi Fan, Nathanael S. Gray, Shifeng Pan
-
Publication number: 20090216024Abstract: Pioglitazone can be made via a Darzens Condensation reaction in an industrially useful process.Type: ApplicationFiled: April 27, 2009Publication date: August 27, 2009Inventors: Jie Zhu, Lambertus Thijs
-
Publication number: 20090209588Abstract: Novel compounds of the general formula (I), in which the variables are as defined in claim 1, the use of these compounds as pharmaceutical compositions, pharmaceutical compositions comprising the compounds and methods of treatment employing these compounds and compositions. The present compounds are useful in the treatment and/or prevention of conditions mediated by Peroxisome Proliferator-Activated Receptors (PPAR), in particular the PPAR? subtype, namely, type 1 diabetes, type 2 diabetes, dyslipidaemia, syndrome X (including the metabolic syndrome, i.e. impaired glucose tolerance, insulin resistance, hyper-triglyceridaemia and/or obesity), cardiovascular diseases (including atherosclerosis) and hypercholesterolaemia.Type: ApplicationFiled: May 3, 2005Publication date: August 20, 2009Applicant: Novo Nordisk A/SInventors: Miroslav Havranek, Per Sauerberg, Ingrid Pettersson, Pavel Pihera, Søren Ebdrup
-
Publication number: 20090176111Abstract: The present invention relates to a splayant, that is, an intercalant/exfoliant, comprising an azinium compound capable of splaying a layered material.Type: ApplicationFiled: March 11, 2009Publication date: July 9, 2009Inventors: Debasis Majumdar, Deepak Shukla
-
Publication number: 20090176837Abstract: Disclosed herein are novel compounds with activity at RAR? 2 receptors. Further disclosed are the use of such compounds for treatment of or to alleviate symptoms of cancer, neurological disorders such as memory deficits and schizophrenia, neurodegenerative disorders such as Parkinson's and Alzheimer's diseases, inflammatory disorders such as psoriasis and rheumatoid arthritis, eye disorders and depression.Type: ApplicationFiled: July 12, 2006Publication date: July 9, 2009Applicant: SONY CORPORATIONInventors: Roger Olsson, Fabrice Piu, Birgitte Lund
-
Patent number: 7541472Abstract: Compounds of formula I are described: along with compositions thereof, methods of use thereof (particularly as fungicides), and methods of making the same.Type: GrantFiled: May 24, 2005Date of Patent: June 2, 2009Assignee: Cropsolution, Inc.Inventors: Richard Anderson, Shy-Fuy Lee, Vivian Du, Takeo Hokama, Rafael Oey, Patricia Arakaki
-
Publication number: 20090124665Abstract: The present invention relates to compounds having the structure (I) useful as potassium channel inhibitors to treat cardiac arrhythmias, and the like.Type: ApplicationFiled: July 18, 2006Publication date: May 14, 2009Inventors: B. Wesley Trotter, Kausik K. Nanda, Scott E. Wolkenberg, M. Brad Nolt, David Wisnoski
-
Publication number: 20090105288Abstract: The present invention relates to compounds of Formula I as shown below, wherein the definitions of A, X, R1, R3, R4, R5, R6, R7, R8, and R9 are provided in the specification. Compounds of Formula I are useful for the treatment of diseases associated with ?-secretase activity, including Alzheimer's disease.Type: ApplicationFiled: October 17, 2008Publication date: April 23, 2009Inventor: Chih Yung HO
-
Patent number: RE40703Abstract: The novel benzamide derivative represented by formula (1) and the novel anilide derivative represented by formula (13) of this invention has differentiation-inducing effect, and are, therefore, useful a therapeutic or improving agent for malignant tumors, autoimmune diseases, dermatologic diseases and parasitism. In particular, they are highly effective as an anticancer drug, specifically to a hematologic malignancy and a solid carcinoma.Type: GrantFiled: October 3, 2006Date of Patent: April 28, 2009Assignee: Schering AktiengesellschaftInventors: Tsuneji Suzuki, Tomoyuki Ando, Katsutoshi Tsuchiya, Osamu Nakanishi, Akiko Saito, Takashi Yamashita, Yoshinori Shiraishi, Eishi Tanaka